Related Experiment Videos
[Vaccination of the newborn against hepatitis B in Burundi]
Insights
Hepatitis B vaccination at birth in Burundi shows high antibody levels. Two doses plus a booster resulted in 82% of infants having protective antibodies, demonstrating vaccine effectiveness.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Context:
- Neonatal hepatitis B vaccination program in Bujumbura, Burundi.
- Utilizes a two-dose primary vaccination schedule with a booster at one year.
- Compares outcomes against a control group.
Purpose:
- To evaluate the immunogenicity of a specific hepatitis B vaccination protocol in newborns.
- To assess the effectiveness of the hepatitis B vaccine in preventing infection in infants.
- To compare antibody levels in vaccinated infants versus unvaccinated controls.
Summary:
- The vaccination protocol involves an initial dose within 48 hours of birth, a second dose at two months, and a booster at one year.
- At the time of the booster dose, 82% of vaccinated infants had developed anti-HBs antibodies.
- Six months post-second dose, all vaccinated infants demonstrated protective anti-HBs antibody levels.
Impact:
- Demonstrates the high efficacy of the hepatitis B vaccine in the studied population.
- Provides evidence supporting the current neonatal vaccination schedule in Burundi.
- Highlights the importance of timely vaccination for achieving herd immunity and disease prevention.
Abstract:
Vaccination against hepatitis B is carried out at birth in the Bujumbura Hospital in Burundi. The vaccination protocol comprises only two injections, the first being given during the first 48 hours after birth and the second two months later. A booster is given at the age of one year. The results of this vaccination programme are compared with those obtained in a control population. At the time of the booster, 82% of vaccinated subjects had anti-HBs antibodies, compared with 3% of control subjects. Six months after the second injection, all vaccinated subjects had anti-HBs antibodies.